Novel Intranasal H5N1 Vaccine Shows Promise Against Bird Flu Pandemic Threat in Preclinical Trials

Researchers at Washington University School of Medicine in St. Louis have developed a novel intranasal vaccine for the highly pathogenic avian influenza A(H5N1) virus, commonly known as bird flu, demonstrating robust immune responses and complete protection against infection in preclinical animal models. This breakthrough, published on January 30 in Cell Reports Medicine, addresses critical challenges in influenza vaccine development, particularly the potential for widespread transmission of H5N1 and the complicating factor of pre-existing immunity from seasonal flu. The innovative vaccine platform, delivered through the nose, aims to provide superior protection against initial infection in the upper respiratory tract, a crucial step in preventing human-to-human transmission and mitigating the risk of a future pandemic.

The Escalating Threat of H5N1 Avian Influenza

The H5N1 avian influenza virus has been a persistent concern for global public health for decades, with its first identification in the United States occurring in 2014. Since its initial emergence, the virus has shown a concerning capacity to evolve and cross species barriers. Initially confined largely to wild bird populations, H5N1 has progressively spread to a broader range of animals, including domestic poultry, various mammalian species, and most recently, dairy cows across multiple U.S. states. This zoonotic leap into livestock represents a significant escalation of the threat, as it increases the opportunities for the virus to adapt further and potentially gain the ability to spread efficiently among humans.

Globally, H5N1 has caused hundreds of human infections since the mid-1990s, with a case fatality rate historically exceeding 50% in reported cases, though recent strains show variation. In the U.S., more than 70 human cases of H5N1 have been reported since 2022, including two fatalities, primarily among individuals with direct exposure to infected animals. The World Health Organization (WHO) and other public health agencies continually monitor the evolution of H5N1, recognizing that its widespread circulation in animal populations provides ongoing opportunities for genetic mutations. These adaptations could enable the virus to transmit more easily between humans, raising alarms about the potential for a devastating influenza pandemic, reminiscent of the 1918 Spanish Flu or the more recent 2009 H1N1 pandemic. The economic toll on the poultry industry alone has been staggering, with millions of birds culled to control outbreaks, underscoring the broad impact of this pathogen.

A Novel Approach to Pandemic Preparedness: Mucosal Immunity

To counter the growing threat and reduce the risk of widespread human transmission, the Washington University research team focused on developing a vaccine administered intranasally rather than via traditional injection. The rationale behind this approach is rooted in immunology: respiratory viruses like influenza primarily initiate infection in the mucosal linings of the nose and upper airways. An intranasal vaccine can stimulate a robust local immune response, including secretory IgA antibodies, directly at these entry points. This mucosal immunity is considered superior for blocking initial infection and subsequent viral shedding, thereby offering the potential to prevent not only severe disease but also the transmission of the virus.

"This particular version of bird flu has been around for some time, but the unique and totally unexpected event where it jumped across species into dairy cows in the United States was a clear sign that we should prepare for the event that a pandemic may occur," stated Jacco Boon, PhD, a professor in the WashU Medicine John T. Milliken Department of Medicine and co-senior author of the study. He emphasized the critical advantage: "Our vaccine to the nose and upper airway — not the shot-in-the-arm vaccine people are used to — can protect against upper respiratory infection as well as severe disease. This could provide better protection against transmission because it protects against infection in the first place."

Preclinical Success: Robust Protection in Animal Models

The preclinical studies, conducted in hamsters and mice, yielded highly encouraging results. The intranasal vaccine consistently triggered strong systemic and mucosal immune responses, effectively preventing H5N1 infection after exposure. Both animal models demonstrated near-complete protection, a significant finding given the high pathogenicity of H5N1. Critically, the nasal spray vaccine consistently provided stronger protection compared to the same vaccine delivered via traditional intramuscular injection, particularly in preventing infection in the respiratory tract. Notably, this robust protection was observed even when the vaccine was administered at low doses and followed by high levels of viral exposure, indicating a high degree of potency and efficacy.

Overcoming the Challenge of Prior Immunity

A key hurdle in influenza vaccine development is the phenomenon of "original antigenic sin" or immune imprinting. This occurs when an individual’s immune system, having been exposed to a particular influenza strain through prior infection or vaccination, preferentially mounts an immune response against that original strain when encountering a new, antigenically distinct strain. This can sometimes weaken the immune response to novel influenza vaccines, reducing their effectiveness. This challenge is particularly relevant for H5N1, as most adults have a history of seasonal flu infections or vaccinations.

The WashU team specifically addressed this issue. Their research demonstrated that the nasal vaccine remained highly effective even in animals with pre-existing immunity to seasonal influenza. "In additional experiments, the researchers examined whether immunity from previous flu infections or vaccinations would interfere with the H5N1 vaccine’s performance. They found that the nasal vaccine continued to provide strong protection even when prior flu immunity was present," the study noted. This capability is vital for real-world application, as it ensures the vaccine’s potential efficacy across diverse populations with varying immune histories.

Leveraging Established Adenovirus-Based Vaccine Technology

The development of this H5N1 vaccine builds upon a well-established and validated vaccine technology platform previously pioneered at WashU Medicine by study co-authors Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine, and David T. Curiel, MD, PhD, a professor of radiation oncology. This platform utilizes a harmless, non-replicating adenovirus as a delivery vehicle to introduce the desired antigen into the body, prompting an immune response without causing infection.

This same adenovirus-based platform has already proven its utility in the fight against other respiratory pathogens. A COVID-19 vaccine developed using this technology received approval for use in India in 2022 and subsequently gained approval for clinical testing in the U.S. last year. The successful deployment and clinical validation of this platform for COVID-19 provide a strong foundation and accelerate the potential pathway for the H5N1 nasal vaccine towards human trials and eventual public health implementation.

Precision Antigen Design for Optimal Recognition

For any vaccine to be effective, the immune system must be able to quickly and accurately recognize the target virus. The WashU team employed a sophisticated approach to antigen design, led by Dr. Boon and co-author Eva-Maria Strauch, PhD, an associate professor of medicine with expertise in antivirals and protein design. They meticulously selected specific proteins from H5N1 strains known to have infected humans. By identifying shared features among these viral proteins, they engineered an optimized antigen – the specific part of the virus that triggers an immune response. This rationally designed antigen was then inserted into the adenovirus delivery system, ensuring that the vaccine presents the most relevant viral components to the immune system for a robust and protective response. This method of antigen design and adenovirus delivery closely mirrors the approach successfully used for the COVID-19 nasal vaccine, highlighting the adaptability and power of the platform.

Broader Implications for Global Health and Pandemic Preparedness

The potential impact of this intranasal H5N1 vaccine extends far beyond just bird flu. The successful application of this mucosal delivery platform, particularly its ability to induce strong local immunity and overcome prior immunity challenges, holds significant promise for developing vaccines against other respiratory pathogens. The current landscape of H5N1 vaccines is limited; while some H5N1 vaccines exist, they were often designed using older virus strains, may not be broadly effective against current circulating H5N1 clades, and are not widely available or stockpiled in sufficient quantities for a pandemic response. Furthermore, many existing flu vaccines are produced using egg-based methods, which can be time-consuming and pose challenges if the pandemic strain does not grow well in eggs. The adenovirus platform offers a rapid, cell-based production method, which could be critical in a fast-moving pandemic scenario.

Dr. Michael Diamond further elaborated on the broader implications, stating, "We’ve shown that this nasal vaccine delivery platform we conceived, designed and conducted initial testing on at WashU Medicine can prevent H5N1 infection from taking hold in the nose and lungs. Delivering vaccine directly to the upper airway where you most need protection from respiratory infection could disrupt the cycle of infection and transmission. That’s crucial to slowing the spread of infection for H5N1 as well as other flu strains and respiratory infections." This shift in vaccine strategy from solely preventing severe disease to actively blocking transmission could revolutionize how public health agencies approach future respiratory pandemics.

The Road Ahead: From Preclinical Success to Clinical Application

While the preclinical results are highly promising, the research team acknowledges that significant steps remain before this vaccine can be made available for human use. The immediate next steps include conducting further detailed studies in larger animal models and utilizing organoids that accurately model human immune tissue to gain a deeper understanding of the vaccine’s protective mechanisms and optimize its formulation. The team is also actively working on updated versions of the vaccine, aiming to further reduce any potential influence of prior seasonal flu immunity and to enhance the breadth and antiviral responses elicited by the vaccine.

The pathway from laboratory discovery to widespread clinical application involves rigorous regulatory processes, including phase I, II, and III human clinical trials to assess safety, immunogenicity, and efficacy in diverse populations. Manufacturing scale-up, funding acquisition, and public acceptance of a novel vaccine delivery method will also be critical factors influencing its eventual deployment. However, the demonstrated efficacy in preclinical models, coupled with the proven safety and scalability of the adenovirus platform, positions this intranasal H5N1 vaccine as a leading contender in the global effort to prepare for and prevent the next influenza pandemic.

Funding and Conflicts of Interest

This study received vital financial support from the Cooperative Center for Human Immunology (U19AI181103) and the Center for Research on Structural Biology of Infectious Diseases (75N93022C00035).

The Boon laboratory has received funding from Novavax Inc for the development of an influenza virus vaccine and unrelated funding support from AbbVie Inc. M.S.D. is a consultant for or serves on the Scientific Advisory Board of Inbios, IntegerBio, Akagera Medicines, GlaxoSmithKline, Merck, and Moderna. The Diamond laboratory has received unrelated funding support through sponsored research agreements from Moderna. These disclosures are standard practice in scientific reporting to ensure transparency regarding potential conflicts of interest.